Mortality and HRs for death of children eligible for enrolment in the MVEPI trial, according to number of doses of oral polio vaccine in campaigns prior to assessment of eligibility
| N | Deaths/person years (PYRS) | Mortality rate (per 1000 PYRS) | HR 95% CI* | P value test of interaction | |
| Children 12–35 months at eligibility assessment | |||||
| 0–2 doses | 0.005 | ||||
| Restrictive MV policy | 580 | 16/1651 | 9.7 | 1.00 (ref) | |
| MV for all | 597 | 28/1631 | 17.2 | 1.69 (0.97 to 2.95) | |
| ≥3 doses | |||||
| Restrictive MV policy | 793 | 28/2046 | 13.7 | 1.00 (ref) | |
| MV for all | 808 | 17/2092 | 8.1 | 0.54 (0.31 to 0.97) | |
| All Children | |||||
| 0–2 doses | 0.004 | ||||
| Restrictive MV policy | 1474 | 49/4471 | 11.0 | 1.00 (ref) | |
| MV for all | 1548 | 72/4637 | 15.5 | 1.38 (0.99 to 1.94) | |
| ≥3 doses | |||||
| Restrictive MV policy | 865 | 32/2304 | 13.9 | 1.00 (ref) | |
| MV for all | 880 | 3/254 | 11.8 | 0.57 (0.33 to 0.98) | |
*Estimated in a Cox proportional hazards model stratified for region and pretrial mortality level. 95% CI estimated using a robust SE accounting for intra-cluster correlation.
MV, measles vaccine.